ClinicalTrials.gov record
Not listed Phase 2 Interventional

Docetaxel and Vinorelbine Plus Filgrastim in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT00006215

Public ClinicalTrials.gov record NCT00006215. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 6:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study of Docetaxel and Vinorelbine in Advanced Non-Small Cell Lung Carcinoma

Study identification

NCT ID
NCT00006215
Recruitment status
Not listed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Amgen
Industry
Enrollment
Not listed

Conditions and interventions

Conditions

Interventions

  • docetaxel Drug
  • filgrastim Biological
  • vinorelbine tartrate Drug

Drug · Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 1999
Primary completion
Not listed
Completion
Not listed
Last update posted
Dec 18, 2013

Started 1999

United States locations

U.S. sites
19
U.S. states
11
U.S. cities
18
Facility City State ZIP Site status
Gould Medical Group Modesto California 95353
Sibley Memorial Hospital Washington D.C. District of Columbia 20016
Veterans Affairs Medical Center - Washington, DC Washington D.C. District of Columbia 20422
Georgia Cancer Treatment Center, P.C. Riverdale Georgia 30274
Oncology and Hematology Associates Westwood Kansas 66205
Veterans Affairs Medical Center - Brooklyn Brooklyn New York 11209
Hematology-Oncology Associates of Rockland, P.C. New City New York 10956
New York Medical College Valhalla New York 10595
Cleveland Clinic Taussig Cancer Center Cleveland Ohio 44195
Community Oncology Group Independence Ohio 44131
CCOP - Dayton Kettering Ohio 45429
CCOP - Toledo Community Hospital Oncology Program Toledo Ohio 43623-3456
Charleston Hematology-Oncology, P.A. Charleston South Carolina 29403
Trident Palmetto Hematology/Oncology North Charleston South Carolina 29406
Boston Baskin Cancer Group, University Tennessee Oncology/Hematology Group Memphis Tennessee 38119
Texas Cancer Care Fort Worth Texas 76104
University of Texas Medical Branch Galveston Texas 77555-0209
Hematology & Oncology Associates of Virginia Richmond Virginia 23226
Morgantown Internal Medicine Group Morgantown West Virginia 26505

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00006215, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 18, 2013 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00006215 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →